Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
52 More Nichi-Iko Products Face Supply Stoppage as Risk Assessment Continues
With internal risk assessments ongoing, Nichi-Iko Pharmaceutical says that the supply of 52 additional products will be stopped as the company would be unable to resume their manufacturing before the exhaustion of their channel inventories, according to a notice to…
To read the full story
Related Article
- Nichi-Iko Expects Shipment Controls to Linger beyond April Next Year for 110 Products
July 1, 2021
- Nichi-Iko Reveals Possible Supply Delays for 164 Products, Stirs Confusion at Peers, Customers
April 23, 2021
- Supply Delays Likely for 160 Nichi-Iko Products despite Biz Suspension Lifted
April 22, 2021
BUSINESS
- Sanofi Debuts Sarclisa SC, Cutting Dosing Time
August 28, 2026
- Daiichi Starts Global PIII of Datroway in Adjuvant Urothelial Cancer
August 28, 2026
- FDA Accepts Kowa’s Glaucoma Drug K-911 for Review
August 28, 2026
- Hokuriku Downpours Cripple Some Drug Deliveries; Wholesalers Report No Damage
August 28, 2026
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…